PLIANT THERAPEUTICS, INC. Income Statement
PLRX|6 years of annual SEC 10-K data (FY2020-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 6 fiscal years. All figures from audited SEC 10-K filings.
PLIANT THERAPEUTICS, INC. reported $0 in revenue and $210M in net loss for FY2025. Revenue has declined at a 35.8% compound annual rate over the past 4 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -4.20 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $9.7M | $7.6M | $7.6M | $57.1M | $57.1M |
| SG&A Expense | $59.1M | $39.9M | $27.6M | $27.6M | $10.9M | $10.9M |
| R&D Expense | $169.3M | $96.9M | $77.5M | $77.5M | $47.4M | $47.4M |
| Operating Income | -$228.4M | -$127.2M | -$97.5M | -$97.5M | -$1.2M | -$1.2M |
| Interest Expense | - | - | $0 | $0 | - | - |
| Income Tax | $0 | $0 | $0 | $0 | - | $0 |
| Net Income | -$210.3M | -$123.3M | -$97.3M | -$97.3M | -$631.0K | -$631.0K |
| EPS (Basic) | -$3.47 | -$2.94 | -$2.71 | -$2.71 | -$4.22 | -$4.22 |
| EPS (Diluted) | -$3.47 | -$2.94 | -$2.71 | -$2.71 | -$4.22 | -$4.22 |
| Shares Outstanding | 60.9M | 59.9M | 48.9M | 36.1M | 35.6M | 1.8M |
| Operating Margin | - | -1313.4% | -1288.1% | -1288.1% | -2.2% | -2.2% |
| Profit Margin | - | -1273.3% | -1284.5% | -1284.5% | -1.1% | -1.1% |